Milciclib Maleate

DRUG3 trials

Sponsors

Tiziana Life Sciences LTD

Conditions

Hepatocellular CarcinomaMalignant ThymomaThymic Carcinoma

Phase 2

Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma

TerminatedNCT01011439

Tiziana Life Sciences LTDThymic Carcinoma

Start: 2010-02-22End: 2018-12-17Updated: 2019-02-06

Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy

TerminatedNCT01301391

Tiziana Life Sciences LTDMalignant Thymoma

Start: 2011-02-02End: 2018-12-17Updated: 2019-02-06

Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma

CompletedNCT03109886

Tiziana Life Sciences LTDHepatocellular Carcinoma

Start: 2017-07-12End: 2019-06-20Updated: 2021-10-12

Related Papers

Phase IIa safety and efficacy of milciclib, a pan-cyclin dependent kinase inhibitor, in unresectable, sorafenib-refractory or -intolerant hepatocellular carcinoma patients.

Journal of Clinical Oncology2020-05-208 citations

Efficacy of milciclib (PHA-848125AC), a pan-cyclin d-dependent kinase inhibitor, in two phase II studies with thymic carcinoma (TC) and B3 thymoma (B3T) patients.

Journal of Clinical Oncology2018-05-2029 citations

A phase II study of milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC).

Journal of Clinical Oncology2014-05-2023 citations